Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Sophia L, Yohe"'
Autor:
Amy K. Beckman, Valerie L. Ng, David L. Jaye, Manila Gaddh, Sarah A. Williams, Sophia L. Yohe, Lin Zhang, Michael A. Linden
Publikováno v:
Diagnostic Pathology, Vol 15, Iss 1, Pp 1-9 (2020)
Abstract Background Peripheral blood smears are performed to evaluate a variety of hematologic and non-hematologic disorders. At the authors’ institutions, clinician requests for pathologist-performed blood smear reviews have increased in recent ye
Externí odkaz:
https://doaj.org/article/ae8642f161ee4075b428b161a3e95e33
Autor:
Daniel F. Hayes, Roy S. Herbst, Jonathan L. Myles, Suzanne L. Topalian, Sophia L. Yohe, Naomi Aronson, Andrew M. Bellizzi, Upal Basu Roy, Georganne Bradshaw, Robin H. Edwards, Ehab A. El-Gabry, Julia Elvin, Thomas F. Gajewski, Lisa M. McShane, Matthew Oberley, Reena Philip, David L. Rimm, Jason N. Rosenbaum, Eric H. Rubin, Lisa Schlager, Shimere W. Sherwood, Mark Stewart, Janis M. Taube, Magdalena Thurin, Patricia Vasalos, Jordan Laser
Publikováno v:
JCO precision oncology. 6
PURPOSE Immune checkpoint inhibition (ICI) therapy represents one of the great advances in the field of oncology, highlighted by the Nobel Prize in 2018. Multiple predictive biomarkers for ICI benefit have been proposed. These include assessment of p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b0574760ad592209cc71ea721097435c
https://pubmed.ncbi.nlm.nih.gov/36446042
https://pubmed.ncbi.nlm.nih.gov/36446042
Autor:
Andrew C, Nelson, Sophia L, Yohe
Publikováno v:
The Journal of molecular diagnostics : JMD. 23(7)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::abf10b799db0ea4f4dd53ee5318c1681
https://pubmed.ncbi.nlm.nih.gov/33964451
https://pubmed.ncbi.nlm.nih.gov/33964451
Autor:
Andrew Schade, Eric E Walk, Anna B Berry, Sophia L Yohe, Amy Beckman, Mary M. Zutter, John D. Pfeifer
Publikováno v:
Archives of pathologylaboratory medicine. 144(6)
Context.—Cancer immunotherapy provides unprecedented rates of durable clinical benefit to late-stage cancer patients across many tumor types, but there remains a critical need for biomarkers to accurately predict clinical response. Although some ca
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5ef117ea32eab8b185ec8f045a8cf613
https://pubmed.ncbi.nlm.nih.gov/31714809
https://pubmed.ncbi.nlm.nih.gov/31714809